Study shows 98% of dermatologists would utilize Mind.Px to predict biologic response for psoriasis patients
SAN DIEGO – July 26, 2021 – Mindera Corporation today announced that Dermatology and Therapy published results from a survey of 43 community-based dermatologists on behaviors and preferences of psoriasis-treating physicians. The survey revealed a widespread and costly trial-and-error cycle in psoriasis biologic decision making, resulting in suboptimal patient outcomes and high wasted spending by payers.
Additionally, physicians expressed enthusiasm for Mind.Px™, a new precision medicine test that predicts individual patient response to psoriasis biologic classes with a high level of predictive value before a physician selects a biologic. In contrast to the current trial-and-error prescribing behavior, the survey revealed that dermatologists view Mind.Px as a move towards dermatologic precision medicine. Highlights of survey findings include:
- 82% of dermatologists report switching biologics for 10-30% of their patients within the first year of prescription
- 93% of dermatologists would utilize the Mind.Px test results over their own initial clinical choice
- 100% of dermatologists would use Mind.Px if it were integrated into the prior authorization process
- 98% of dermatologists say that Mind.Px would improve patient outcomes
The study was authored by key opinion leaders and authors of the Joint American Academy of Dermatology/National Psoriasis Foundation Guidelines of Care for the Management and Treatment of Psoriasis with Biologics, including Bruce Strober, MD PhD, David Pariser MD, Mark Lebwohl, MD, and Alan Menter, MD. The guidelines, published in 2019, stated that there is “an important need to identify biomarkers that can potentially predict the appropriate biologic agent of individual patients.”
“Having the ability to proactively predict response to a biologic class with Mind.Px will enable physicians to finally have a tool to better prescribe the appropriate therapy the first time, significantly improving patient outcomes,” said Dr. Strober. “The potential benefits to the patient and the healthcare system are groundbreaking and the survey clearly shows the perceived clinical utility of this test.”
Mind.Px is the flagship test of Mindera Corporation. The Mindera platform uses a dermal biomarker patch that takes only minutes to extract vast transcriptomic information. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera scientists to take a genetic and transcriptomic snapshot of the skin. This rich patient-specific data set is then analyzed by machine learning algorithms to predict the appropriate biologic drug for an individual patient prior to therapeutic selection and treatment.
The ability to collect patient data at scale results in a powerful platform that unlocks cost savings for healthcare systems, particularly when applied to the prediction of response to hyper-expensive treatments. Biomarkers captured using the Mindera platform include DNA, RNA, protein, and small molecules.
Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera is a CLIA and CAP certified Laboratory and has received ISO 13485:2016 certification. Find out more at www.minderadx.com.